Did SKYRIZI’s Subcutaneous Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?

Earlier this week, AbbVie reported Phase 3 AFFIRM data showing subcutaneous SKYRIZI induced endoscopic remission and ulcer-free endoscopy in a meaningful share of adults with moderately to severely active Crohn’s disease, with safety consistent with its existing profile. The findings, presented at the 2026 American College of Gastroenterology meeting, could support regulatory reviews of a more convenient subcutaneous induction option and deepen AbbVie’s presence in difficult-to-treat...